New drug combo aims to shrink tough lung tumors
NCT ID NCT07697586
First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time
Summary
This phase II trial is testing whether a combination of two drugs, SKB264 and SKB118, can safely shrink tumors in people with advanced non-small cell lung cancer that has spread. The study includes a dose-finding phase and an expansion phase to better understand the treatment's effects. Participants must have a specific type of lung cancer without certain gene mutations and be in generally good health.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Sacituzumab tirumotecan (SKB264) and SKB118
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced non-small cell lung cancer who have limited alternatives.
- What could go wrong
- This is an early phase II trial, so the combination may not prove effective or could cause significant side effects. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jilin Cancer Hospital
Jilin City, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shanghai East Hospital, Tongji University
Shanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Pronged antibody boost Chemo's power against lung cancer?
- New drug combo aims to outsmart lung cancer that resists immunotherapy
- Blood test may let cancer patients take safe breaks from immunotherapy
- New targeted pill aims to shrink lung tumors in patients with common gene mutation
- Lung cancer drug interaction study aims to uncover safe dosing
- New PET scan could predict who benefits from targeted lung cancer therapy